Open label study of ONTAK (denileukin diftitox, DAB389 IL-2) to estimate response in cutaneous T-cell lymphoma (CTCL) according to CD25 status.

Trial Profile

Open label study of ONTAK (denileukin diftitox, DAB389 IL-2) to estimate response in cutaneous T-cell lymphoma (CTCL) according to CD25 status.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2012

At a glance

  • Drugs Denileukin diftitox (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Ligand Pharmaceuticals
  • Most Recent Events

    • 16 Apr 2012 Company (Ligand Pharmaceuticals) added and additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 05 Aug 2011 Actual end date (Sep 2006) added as reported by ClinicalTrials.gov.
    • 05 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top